HealthEquity, Inc. $HQY Shares Sold by Physician Wealth Advisors Inc.

Physician Wealth Advisors Inc. cut its stake in shares of HealthEquity, Inc. (NASDAQ:HQY) by 38.7% in the 3rd quarter, HoldingsChannel reports. The firm owned 28,862 shares of the company’s stock after selling 18,183 shares during the period. Physician Wealth Advisors Inc.’s holdings in HealthEquity were worth $2,553,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Fifth Third Wealth Advisors LLC raised its holdings in shares of HealthEquity by 4.2% during the 1st quarter. Fifth Third Wealth Advisors LLC now owns 2,872 shares of the company’s stock valued at $240,000 after buying an additional 116 shares in the last quarter. GAMMA Investing LLC raised its holdings in HealthEquity by 12.0% during the 3rd quarter. GAMMA Investing LLC now owns 1,479 shares of the company’s stock valued at $131,000 after buying an additional 158 shares during the last quarter. Cim Investment Management Inc. boosted its holdings in shares of HealthEquity by 5.0% during the second quarter. Cim Investment Management Inc. now owns 4,007 shares of the company’s stock worth $362,000 after purchasing an additional 191 shares during the period. State of Michigan Retirement System lifted its stake in HealthEquity by 1.0% in the first quarter. State of Michigan Retirement System now owns 20,522 shares of the company’s stock worth $1,715,000 after acquiring an additional 200 shares during the period. Finally, Leonteq Securities AG raised its holdings in HealthEquity by 159.9% in the 1st quarter. Leonteq Securities AG now owns 382 shares of the company’s stock worth $32,000 after purchasing an additional 235 shares in the last quarter. Hedge funds and other institutional investors own 99.55% of the company’s stock.

HealthEquity Stock Performance

Shares of NASDAQ HQY opened at $96.60 on Wednesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.99 and a current ratio of 2.99. The company has a market cap of $7.99 billion, a P/E ratio of 34.87, a P/E/G ratio of 1.47 and a beta of 0.24. HealthEquity, Inc. has a 52-week low of $72.76 and a 52-week high of $107.62. The firm’s fifty day moving average is $95.62 and its two-hundred day moving average is $91.63.

HealthEquity (NASDAQ:HQY) last announced its quarterly earnings results on Thursday, August 27th. The company reported $1.24 EPS for the quarter, beating analysts’ consensus estimates of $1.19 by $0.05. The company had revenue of $350.73 million during the quarter, compared to analyst estimates of $349.22 million. HealthEquity had a return on equity of 15.33% and a net margin of 17.36%. HealthEquity’s revenue was up 95.5% on a year-over-year basis. HealthEquity has set its FY 2027 guidance at 4.660-4.730 EPS. As a group, analysts anticipate that HealthEquity, Inc. will post 3.93 EPS for the current fiscal year.

Insider Activity at HealthEquity

In related news, Director Adrian Dillon sold 7,632 shares of the stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $104.61, for a total value of $798,383.52. Following the completion of the transaction, the director owned 62,395 shares of the company’s stock, valued at approximately $6,527,140.95. This trade represents a 10.90% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.60% of the company’s stock.

Analyst Upgrades and Downgrades

HQY has been the topic of a number of research analyst reports. Barclays upped their target price on HealthEquity from $110.00 to $115.00 and gave the stock an “overweight” rating in a report on Friday, September 18th. Telsey Advisory Group set a $111.00 target price on shares of HealthEquity in a report on Friday, August 28th. Raymond James Financial reissued a “strong-buy” rating on shares of HealthEquity in a research report on Thursday, September 3rd. Weiss Ratings upgraded HealthEquity from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on shares of HealthEquity from $135.00 to $142.00 and gave the company a “buy” rating in a research report on Monday, August 31st. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $112.20.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled benefits administration and financial services that help employers and individuals manage tax-advantaged healthcare accounts. The company’s offerings include health savings accounts (HSAs), flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), and other consumer-directed benefits.

In addition to account administration, HealthEquity provides payment cards, investment options for eligible account holders, employee engagement tools, and digital platforms for managing healthcare benefits.